1. Signaling Pathways
  2. Immunology/Inflammation
  3. Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most (clusters of differentiation)CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells[1][2].

Transmembrane Glycoprotein Related Products (199):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99227
    Caplacizumab
    ≥99.0%
    Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP).
    Caplacizumab
  • HY-P99057
    Varlilumab
    Inhibitor
    Varlilumab (CDX-1127) is an agonist anti-CD27 monoclonal antibody. Varlilumab can promote T cell expansion and activate the immune response. Varlilumab has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors.
    Varlilumab
  • HY-P99129
    Anti-Mouse CD8a Antibody (53-6.7)
    Inhibitor
    Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice.
    Anti-Mouse CD8a Antibody (53-6.7)
  • HY-P99329
    Vadastuximab
    99.23%
    Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine.
    Vadastuximab
  • HY-P99363
    Feladilimab
    Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer.
    Feladilimab
  • HY-P1242
    NEP(1-40)
    Antagonist 99.40%
    NEP(1-40) is a Nogo-66 receptor (NgR) antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition.
    NEP(1-40)
  • HY-P99233
    Camidanlumab
    Inhibitor 99.23%
    Camidanlumab (HuMax-TAC) is a humanized IgG1 monoclonal antibody against CD25. Camidanlumab can be used to synthesize the ADC molecule Camidanlumab tesirine (HY-141599). Camidanlumab can be used in the research of tumors such as lymphoma and leukemia. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Camidanlumab
  • HY-147329
    RAGE 229
    99.89%
    RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1).
    RAGE 229
  • HY-P990155
    Anti-Mouse TIGIT Antibody (1G9)
    Inhibitor 99.23%
    Anti-Mouse TIGIT Antibody (1G9) is a mouse-derived agonistic TIGIT IgG1 κ type antibody. Anti-Mouse TIGIT Antibody (1G9) blocks CD155 binding to TIGIT. Anti-Mouse TIGIT Antibody (1G9) shows potent anti-infection and anti-immune effects in septic and experimental autoimmune encephalomyelitis.
    Anti-Mouse TIGIT Antibody (1G9)
  • HY-P99414
    Prezalumab
    Inhibitor 99.23%
    Prezalumab (AMG 557) is a humanized IgG2 monoclonal antibody targeting ICOSL. Prezalumab inhibits T cell activation and related immune responses by binding to ICOSL and blocking the interaction between ICOS and ICOSL. Prezalumab can be used in the research of autoimmune diseases and inflammatory diseases such as systemic lupus erythematosus. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
    Prezalumab
  • HY-P9983
    Lintuzumab
    Inhibitor 98.09%
    Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.
    Lintuzumab
  • HY-P99202
    Vibostolimab
    Inhibitor
    Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.
    Vibostolimab
  • HY-P5322
    Thrombospondin (TSP-1)-derived CD36 binding motif
    99.58%
    Thrombospondin (TSP-1)-derived CD36 binding motif is a bioactive hexapeptide. Thrombospondin (TSP-1)-derived CD36 binding motif interferes with the interaction between cells and the extracellular matrix by binding to CD36 and angiostatin, thereby affecting the cell adhesion and migration process. Thrombospondin (TSP-1)-derived CD36 binding motif inhibits platelet aggregation. Thrombospondin (TSP-1)-derived CD36 binding motif exerts an anti-tumor effect against colon cancer.
    Thrombospondin (TSP-1)-derived CD36 binding motif
  • HY-128111
    ASN02563583
    Activator 99.21%
    ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC50 value of 0.64 nM in [35S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases.
    ASN02563583
  • HY-P99858
    Domvanalimab
    Inhibitor
    Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer.
    Domvanalimab
  • HY-144399
    CD33 splicing modulator 1
    Inhibitor 99.55%
    CD33 splicing modulator 1 (Compound 1) is a CD33 splicing modulator. CD33/Siglec 3 is a myeloid lineage cell surface receptor that is known to regulate microglia activity. CD33 splicing modulator 1 increases exon 2 skipping in cellular mRNA pools. CD33 splicing modulator 1 has the potential for the research of neurodegenerative disease including Alzheimer's disease.
    CD33 splicing modulator 1
  • HY-P99128
    Anti-Mouse CD8 beta Antibody (53-5.8)
    Inhibitor
    Anti-Mouse CD8 beta Antibody (53-5.8) is an anti-mouse CD8 beta IgG2a monoclonal antibody. Anti-Mouse CD8 beta Antibody (53-5.8) can deplete CD8+ T cells and enhance cytotoxicity. Anti-Mouse CD8 beta Antibody (53-5.8) can be used for research on immunology.
    Anti-Mouse CD8 beta Antibody (53-5.8)
  • HY-P99958
    Vixtimotamab
    Inhibitor
    Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).
    Vixtimotamab
  • HY-P990282
    Anti-Mouse CD24 Antibody (M1/69)
    Inhibitor
    Anti-Mouse CD24 Antibody (M1/69) is a rat-derived anti-mouse CD24 IgG2b κ type antibody inhibitor. Anti-Mouse CD24 Antibody reduces heat stable antigen (HSA) expression level and delays wound healing in Wild-type HSA+/+ mice.
    Anti-Mouse CD24 Antibody (M1/69)
  • HY-P99566
    Tenatumomab
    Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach.
    Tenatumomab